DMAA vs LLY

Eli Lilly and Company (LLY) offers the better valuation at 41.

3x trailing P/E (26. 3x forward), making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +399.

3%, compared to +6. 4% for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA). Over 10 years, the gap is even starker: LLY returned +1203% versus DMAA's +6. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Drugs Made In America Acquisition Corp.

Ordinary Shares (DMAA) is the lower-risk stock at 0. 00β versus Eli Lilly and Company's 0. 65β — meaning LLY is approximately Infinity% more volatile than DMAA relative to the S&P 500.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus 0. 0% for Drugs Made In America Acquisition Corp. Ordinary Shares — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 0. 0% for DMAA. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, LLY (0.

6% yield) pays a dividend. DMAA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65), 0. 6% yield, +1203% 10Y return). Both have compounded well over 10 years (LLY: +1203%, DMAA: +6. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DMAA (Financial Services) and LLY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DMAA is a small-cap quality compounder stock; LLY is a large-cap high-growth stock. LLY pays a dividend while DMAA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.